Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1583.49%
operating margin TTM
-1647.57%
revenue TTM
2.19 Million
revenue per share TTM
0.25$
valuation ratios | |
|---|---|
| pe ratio | -1.04 |
| peg ratio | -0.33 |
| price to book ratio | 7.35 |
| price to sales ratio | 17.02 |
| enterprise value multiple | -1.40 |
| price fair value | 7.35 |
profitability ratios | |
|---|---|
| gross profit margin | 99.0% |
| operating profit margin | -1647.57% |
| pretax profit margin | -1583.49% |
| net profit margin | -1583.49% |
| return on assets | -199.97% |
| return on equity | -233.03% |
| return on capital employed | -331.59% |
liquidity ratio | |
|---|---|
| current ratio | 2.66 |
| quick ratio | 2.66 |
| cash ratio | 2.08 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 28.80 |
| days of payables outstanding | 24,139.77 |
| cash conversion cycle | -24,110.97 |
| receivables turnover | 12.67 |
| payables turnover | 0.02 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | -52.73 |
| cash flow to debt ratio | 0.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | -5.39 |
| cash per share | 1.62 |
| operating cash flow per share | -3.80 |
| free cash flow operating cash flow ratio | 1.42 |
| cash flow coverage ratios | 0.00 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -2.40 |
Frequently Asked Questions
When was the last time Lumos Pharma, Inc. (NASDAQ:LUMO) reported earnings?
Lumos Pharma, Inc. (LUMO) published its most recent earnings results on 07-11-2024.
What is Lumos Pharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Lumos Pharma, Inc. (NASDAQ:LUMO)'s trailing twelve months ROE is -233.03%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Lumos Pharma, Inc. (LUMO) currently has a ROA of -199.97%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did LUMO's net profit margin stand at?
LUMO reported a profit margin of -1583.49% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is LUMO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.66 in the most recent quarter. The quick ratio stood at 2.66, with a Debt/Eq ratio of 0.00.